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Caprolactam: Condensation of the
Carcinogenesis Bioassay Technical
Report*
Caprolactam (aminocaproic lactam, 2-oxohexa-
methylenimine, CAS No. 105-60-2), the monomer
used in the production ofnylon-6, was selected and
testing initiated by the Carcinogenesis Testing
Program, National Cancer Institute (now part of
the National Institute of Environmental Health
Sciences/NationalToxicologyProgram)becausenearly
one billion pounds per year are produced, because
of the widespread use in food packaging materials
and clothing, and because no carcinogenicity stud-
ies had been done (1).
Nylon 6 resins/fibers are used extensively in
carpets, knit fabrics, hosiery, thread, hairbrushes,
replacement parts for automobiles and machinery,
flotation devices, and food packaging. Highly solu-
ble in water, caprolactam reportedly leaches from
clothing made from polyamide fibers when soaked
insimulatedperspiration(2). FergusonandWheeler
(3) reported irritation of the skin, eyes, nose, and
throat in workers occupationally exposed to capro-
lactam dust or vapor at concentrations ranging
from 10 to 100 ppm.
Methods
Male and female inbred Fischer344rats andmale
and female hybrid B6C3F1 mice, obtained from the
Frederick Cancer Research Center, were used in
this study. Control and treated groups contained 50
animals of each sex and species. For 103 consecu-
tive weeks all groups received Ralston Purina
Laboratory Chow. Treated groups were fed this
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diet containing 3750 or 7500 ppm (rats) and 7500 or
15,000 ppm (mice) caprolactam ( - 100% pure).
This carcinogenesis bioassay was conducted from
January 1977 to February 1979 at Litton Bionetics
under a subcontract to TracorJitco (prime contrac-
tor for the testing program).
All animals that died during the study or that
were killed at the end ofthe exposure period were
subjected to a gross necropsy and a complete
histopathological examination. Statistical analyses
comparing survival and numbers of animals with
specific site tumors were done with trend tests and
pairwise comparisons (4-7). The study design
conformed to the NCI Guidelines for carcinogen
bioassay (8).
Results
Throughout the bioassay, mean body weight
gains fortreated rats and mice decreased (and dose
related) in comparison to controls. For rats, feed
consumption by high dose males and females was
70-80% of that for controls; no difference was
observed for mice. Survival was comparable among
all groups.
The incidences of caprolactam-treated animals
with specific site tumors did not differ significantly
from those diagnosed in controls. Tables 1 (rats)
and 2 (mice) list those primary tumors occurring in
at least three animals of any one group.
Discussion
Pituitary carcinomas in male rats showed a
statistically significant (p < 0.05) positive linear
trend (0/46 control, 0/49 low dose, 3/43 high dose);
femaleratincidenceswere2/49,1/49, 1/47. Comparison
oftreatedgroupswithcontrolsrevealed nostatistical
difference; likewise when adenomas were combined
with carcinomas. This response was not considered
associated with caprolactam administration. Other200 CONDENSATION
Table 1. Primary tumors in male and female F344 rats fed diets containing caprolactam.
Males Females
Tumor Control 3750 ppm 7500 ppm Control 3750 ppm 7500 ppm
Adrenal cortical adenoma 1/49 0/50 0/49 4/48 3/50 2/50
Adrenal pheochromocytoma 10/49 8/50 7/49 2/48 5/50 3/50
Hepatocellular carcinoma 1/50 3/49a 2/50 0/48 0/50 0/50
Leukemia 13/50 11/50 16/50 9/49 10/50 11/50
Mammary gland 3/50 4/50 1/50 12/49 7/50 7/50
Pituitary adenoma or carcinoma 10/46 11/49 11/47 24/49 24/49 16/47
Subcutaneous fibroma or fibrosarcoma 6/50 4/50 1/50 1/49 0/50 0/50
Testicular interstitial cell 41/49 43/50 48/50 - - -
Thyroid C-cell adenoma 3/46 1/45 5/49b 2/44 4/46 6/46
Thyroid follicular cell carcinoma 0/46 0/45 0/49 0/44 1/46 2/46c
Uterine endometrial stromal polyp - - - 12/49 20/50 15/50
'Two other male rats had neoplastic nodules.
bOne other male rat had a thyroid C-cell carcinoma.
cOne other female rat had a thyroid follicular-cell adenoma.
Table 2. Primary tumors in male and female B6C3F1 mice fed diets containing caprolactam.
Males Females
Tumor Control 3750 ppm 7500 ppm Control 3750 ppm 7500 ppm
Circulatory system hemangiosarcoma 0/50 0/50 0/50 3/50 0/49 1/50
Hepatocellular adenoma 3/50 1/50 4/49 0/50 0/49 1/50
Hepatocellular carcinoma 5/50 9/50 6/49 1/50 1/49 0/50
Leukemia 0/50 0/50 1/50 4/50 2/49 0/50
Lymphoma 9/50 6/50 5/50 17/50 21/49 12/50
Lung alveolar/bronchiolar adenoma 3/50 3/50 2/49 3/50 0/49 0/50
Lung alveolar/bronchiolar carcinoma 1/50 2/50 2/49 0/50 0/49 0/50
effects interpreted as being unrelated to the
administration of caprolactam included the nega-
tive trends calculated for papillary adenocarcino-
mas of the mammary gland in female rats (4/49,
1/50, 0/50), for subcutaneous fibromas in male rats
(5/50, 3/50, 0/50), for lung alveolar/bronchiolar ade-
nomas in female mice (3/50, 0/49, 0/50), and for
leukemias/lymphomas of the hematopoietic system
in female mice (4/50, 2/49, 0/50).
Because no evidence ofneoplastic or nonneoplas-
tic lesions could be related to dietary administra-
tion of caprolactam, under the conditions of this
bioassay caprolactam was not carcinogenic for F344
rats or B6C3F1 mice of either sex (9).
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